Saccade velocity as a surrogate disease marker in spinocerebellar ataxia type 2.
We measured in 82 spinocerebellar ataxia type 2 (SCA2) patients and in 80 controls maximal saccade velocity (MSV) and correlated it to polyglutamine expansion size and disease duration. MSV is strongly decreased in SCA2 patients and is influenced mostly by polyglutamine size.
Seifried
C
C
Clinic for Neurology, University Hospital, Frankfurt, am Main, Germany.
Velázquez-Pérez
L
L
Santos-Falcón
N
N
Abele
M
M
Ziemann
U
U
Almaguer
L E
LE
Martínez-Góngora
E
E
Sánchez-Cruz
G
G
Canales
N
N
Pérez-González
R
R
Velázquez-Manresa
M
M
Viebahn
B
B
Stuckrad-Barre
S
S
Klockgether
T
T
Fetter
M
M
Auburger
G
G
D000293:Adolescent; D000328:Adult; D017668:Age of Onset; D000368:Aged; D015415:Biomarkers; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D015835:Ocular Motility Disorders / Q000503:physiopathology*; D010455:Peptides / Q000032:analysis; D012438:Saccades / Q000502:physiology*; D020754:Spinocerebellar Ataxias / Q000175:diagnosis*; D013997:Time Factors
D015415:Biomarkers; D010455:Peptides; C097188:polyglutamine